Overview

SCIENTIFIC SCORE
Possibly Effective
Based on 41 Researches
7.7
USERS' SCORE
Good
Based on 9 Reviews
8
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Blend of Probiotic Bacteria:Lactobacillus acidophilus (La-14),Bifidobacterium lactis (Bl-04),Bifidobacterium longum (Bl-05)
8 Billion CFU
*

Top Medical Research Studies

9.5
CECT 7347 reduces IBS-D symptoms
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.

Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.

Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More
9
Probiotics improve IBS symptoms
This study looked into the effects of two probiotic strains, DDS-1 and UABla-12, on alleviating abdominal pain and other IBS symptoms.

We observed that participants taking these probiotics experienced notable reductions in pain severity and overall symptom scores compared to those receiving a placebo.

Specifically, both probiotic groups reported improved bowel habits and stool consistency, enhancing quality of life for adults facing IBS.

Overall, the results suggest that these probiotic strains can be beneficial for managing symptoms of irritable bowel syndrome.
Read More

Most Useful Reviews

9
Bowel issues resolved
1 people found this helpful
This is a great product; many of my bowel issues disappeared immediately upon using it.
Read More
9
Excellent for IBS
4 people found this helpful
This product has greatly benefited my irritable bowel syndrome. My gynaecologist even credited my daily intake of this with an increase in beneficial bacteria in my uterus. I experienced no bleeding during ovulation, and my bowel movements have also improved significantly.
Read More
6
Odour improvement
2 people found this helpful
I've noticed an improvement in odour, likely due to the balance of my intestinal bacteria improving. This product has also enhanced my bowel movements, making them better than before.
Read More

Medical Researches

SCIENTIFIC SCORE
Possibly Effective
Based on 41 Researches
7.7
  • All Researches
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
CECT 7347 reduces IBS-D symptoms
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.

Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.

Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More
9
Probiotics improve IBS symptoms
This study looked into the effects of two probiotic strains, DDS-1 and UABla-12, on alleviating abdominal pain and other IBS symptoms.

We observed that participants taking these probiotics experienced notable reductions in pain severity and overall symptom scores compared to those receiving a placebo.

Specifically, both probiotic groups reported improved bowel habits and stool consistency, enhancing quality of life for adults facing IBS.

Overall, the results suggest that these probiotic strains can be beneficial for managing symptoms of irritable bowel syndrome.
Read More

User Reviews

USERS' SCORE
Good
Based on 9 Reviews
8
  • All Reviews
  • Positive Reviews
  • Negative Reviews
9
Bowel issues resolved
1 people found this helpful
This is a great product; many of my bowel issues disappeared immediately upon using it.
Read More
9
Excellent for IBS
4 people found this helpful
This product has greatly benefited my irritable bowel syndrome. My gynaecologist even credited my daily intake of this with an increase in beneficial bacteria in my uterus. I experienced no bleeding during ovulation, and my bowel movements have also improved significantly.
Read More
6
Odour improvement
2 people found this helpful
I've noticed an improvement in odour, likely due to the balance of my intestinal bacteria improving. This product has also enhanced my bowel movements, making them better than before.
Read More
7.5
Better bowel movements
1 people found this helpful
I used to suffer from constipation, but since using this product, my bowel movements have improved significantly.
Read More
7.5
Effective for IBS
1 people found this helpful
For digestive issues, especially in establishing regular bowel movements after dysbiosis or surgeries, this product is very effective. I recommend combining it with lactulose or another prebiotic for better results, as they nourish beneficial microflora and enhance effectiveness.
Read More

Frequently Asked Questions

9
Bowel issues resolved
1 people found this helpful
This is a great product; many of my bowel issues disappeared immediately upon using it.
7.5
Consistent bowel movements
5 people found this helpful
I finally achieved consistent bowel movements! I had previously taken NOW Gr 8 - Dophilus with no effect, but over time, this product significantly reduced gas and occasional diarrhoea. Though I still experience some anxiety around bowel movements during weekends, most days are stable now. I've tried gastrointestinal support alongside; I noticed improvements after several weeks. I plan to purchase this again.
7.5
Significantly improved digestion
4 people found this helpful
After nearly a year of use, my irritable bowel syndrome has improved greatly. Heartburn has significantly reduced, and my digestion has improved, leading to better absorption of vitamins and minerals. This has shown positive results in my blood tests. It's one of the best probiotics I've tried, especially for constipation. Currently, I take it with L-Carnitine on an empty stomach, which has further improved my condition.
7.5
Better bowel movements
1 people found this helpful
I used to suffer from constipation, but since using this product, my bowel movements have improved significantly.
7.5
Effective for IBS
1 people found this helpful
For digestive issues, especially in establishing regular bowel movements after dysbiosis or surgeries, this product is very effective. I recommend combining it with lactulose or another prebiotic for better results, as they nourish beneficial microflora and enhance effectiveness.
7.5
Comfortable toilet experience
1 people found this helpful
I found that taking one tablet at night significantly improved my bowel movements the next morning, making the experience comfortable rather than painful.
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
8
Probiotics help relieve IBS symptoms
We investigated the impact of multispecies probiotics, including Lactobacillus acidophilus, in treating irritable bowel syndrome (IBS). In a randomized, double-blind study with 49 participants, those taking probiotics experienced significantly more symptom relief than those on a placebo after four weeks.

The probiotics not only eased abdominal discomfort and bloating but also positively altered gut bacteria. Our findings suggest that multispecies probiotics could be a valuable option for managing IBS symptoms.
8
Lactobacillus aids IBS-related depression
We examined how consuming a cultured milk drink with Lactobacillus acidophilus might impact depression in patients with irritable bowel syndrome (IBS). The study involved 110 participants who were divided into groups to receive either the probiotic drink or a placebo over 12 weeks.

Those with subthreshold depression experienced significant reductions in depression scores. The probiotic group even saw boosts in serotonin levels and improvements in quality of life. Although everyone reported reduced IBS severity, the probiotics specifically showed notable potential in managing depressive symptoms linked to IBS.

References

  1. Sarkawi M, Raja Ali RA, Abdul Wahab N, Abdul Rathi ND, Mokhtar NM. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. Sci Rep. 2024;14:9478. doi:10.1038/s41598-024-60029-2
  2. Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;72:233.
  3. Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;73:233.
  4. Chang YH, Choi YJ, Shin CM, Moon JS, Kim TY, et al. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Neurogastroenterol Motil. 2024;30:73. doi:10.5056/jnm23036
  5. Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
  6. Cocetta V, Giacomini I, Tinazzi M, Berretta M, Quagliariello V, et al. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. Minerva Pediatr (Torino). 2023. doi:10.23736/S2724-5276.23.07128-8
  7. Shin SY, Park S, Moon JM, Kim K, Kim JW, et al. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2022;28:642. doi:10.5056/jnm21202
  8. Mokhtar NM, Jaafar NM, Alfian E, Mohd Rathi ND, Abdul Rani R, et al. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastroenterol Belg. 2021;84:585. doi:10.51821/84.4.009
  9. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
  10. Martoni CJ, Srivastava S, Leyer GJ. DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12. doi:10.3390/nu12020363
  11. Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52:534. doi:10.1016/j.dld.2019.12.009
  12. Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9:697. doi:10.3920/BM2017.0105
  13. Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11:627. doi:10.1007/s12602-018-9401-3
  14. Bogovič Matijašić B, Obermajer T, Lipoglavšek L, Sernel T, Locatelli I, et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J Dairy Sci. 2016;99:5008. doi:10.3168/jds.2015-10743
  15. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
  16. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
  17. Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
  18. Martin FP, Cominetti O, Berger B, Combremont S, Marquis J, et al. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. Gut Microbes. 2024;16:2347715. doi:10.1080/19490976.2024.2347715
  19. Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16:2338322. doi:10.1080/19490976.2024.2338322
  20. Lenoir M, Wienke J, Fardao-Beyler F, Roese N. An 8-Week Course of Bifidobacterium longum 35624 Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2025;17:315. doi:10.1007/s12602-023-10151-w
  21. Khoo XH, Chong CW, Talha AM, Philip K, Teh CS, et al. The impact of diet and ethnicity on gut microbiota variation in irritable bowel syndrome: A multi-center study. J Gastroenterol Hepatol. 2023;38:1259. doi:10.1111/jgh.16174
  22. Nakamura Y, Suzuki S, Murakami S, Nishimoto Y, Higashi K, et al. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by BB536 supplementation: A RCT. Comput Struct Biotechnol J. 2022;20:5847. doi:10.1016/j.csbj.2022.10.026
  23. Yakovenko EP, Strokova TV, Ivanov AN, Iakovenko AV, Gioeva IZ, et al. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study]. Ter Arkh. 2022;94:180. doi:10.26442/00403660.2022.02.201368
  24. Groeger D, Murphy EF, Tan HTT, Larsen IS, O'Neill I, et al. Interactions between symptoms and psychological status in irritable bowel syndrome: An exploratory study of the impact of a probiotic combination. Neurogastroenterol Motil. 2023;35:e14477. doi:10.1111/nmo.14477
  25. Sabaté JM, Iglicki F. Effect of 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28:732. doi:10.3748/wjg.v28.i7.732
  26. Di Pierro F, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15. doi:10.1016/j.clnesp.2020.12.025
  27. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, et al. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020;9. doi:10.3390/jcm9082353
  28. Bonfrate L, Di Palo DM, Celano G, Albert A, Vitellio P, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50:e13201. doi:10.1111/eci.13201
  29. Buhner S, Hahne H, Hartwig K, Li Q, Vignali S, et al. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One. 2018;13:e0193943. doi:10.1371/journal.pone.0193943
  30. JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, et al. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Eur J Nutr. 2024;63:1983. doi:10.1007/s00394-024-03398-8
  31. Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, et al. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing or in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J Clin Med. 2023;12. doi:10.3390/jcm12144838
  32. Boonma P, Shapiro JM, Hollister EB, Badu S, Wu Q, et al. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:691689. doi:10.3389/fpain.2021.691689
  33. Xu H, Ma C, Zhao F, Chen P, Liu Y, et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr. 2021;60:2553. doi:10.1007/s00394-020-02437-4
  34. Szajewska H, Hojsak I. Health benefits of GG and subspecies BB-12 in children. Postgrad Med. 2020;132:441. doi:10.1080/00325481.2020.1731214
  35. Le Nevé B, Derrien M, Tap J, Brazeilles R, Cools Portier S, et al. Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. PLoS One. 2019;14:e0214273. doi:10.1371/journal.pone.0214273
  36. Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol. 2016;27:439. doi:10.5152/tjg.2016.16301
  37. Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638. doi:10.1017/S0007114515003347
  38. Veiga P, Pons N, Agrawal A, Oozeer R, Guyonnet D, et al. Changes of the human gut microbiome induced by a fermented milk product. Sci Rep. 2014;4:6328. doi:10.1038/srep06328
  39. Gomes P, Laroute V, Beaufrand C, Bézirard V, Aubry N, et al. Postbiotic potential of Lactococcus lactis CNCM I-5388 in alleviating visceral pain in female rat through GABA production: The innovative concept of the "active-GAD bag". FASEB J. 2025;39:e70383. doi:10.1096/fj.202401125RR
  40. Gomes P, Laroute V, Beaufrand C, Daveran-Mingot ML, Aubry N, et al. Lactococcus lactis CNCM I-5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress-induced intestinal hypersensitivity in rats. FASEB J. 2023;37:e23264. doi:10.1096/fj.202301588R
  41. Laroute V, Beaufrand C, Gomes P, Nouaille S, Tondereau V, et al. NCDO2118 exerts visceral antinociceptive properties in rat via GABA production in the gastro-intestinal tract. Elife. 2022;11. doi:10.7554/eLife.77100
image